SXSW is back for 2021 — and applications are open for the startup pitch competition. Photo by Marie Ketring via sxsw.org

On March 6, just days before the 2020 SXSW festival was scheduled to begin, local officials issued an emergency order, effectively banning large-scale events in Austin as the novel coronavirus began spreading across the U.S. As a result, SXSW canceled its flagship 10-day festival for the first time ever.

In retrospect, the decision likely saved lives and helped curb the spread of COVID-19, but SXSW's corporate fallout was fast and brutal. Within days, SXSW laid off 30 percent of its Austin-based workforce, and many were left wondering if the festival would ever return.

Finally, a bright spot of news in a dark time: SXSW is back. Yes, it will look different than years past, but beginning Tuesday, November 10, registration is open for SXSW Online, taking place March 16-20, 2021.

"This year has been one like none of us have faced. At SXSW, the impact has been profound and has involved substantial changes in how we work, so it means a lot for us to have the chance to plan a 2021 digital event where we can share experiences and exchange ideas at this crucial time," says SXSW co-founder and CEO Roland Swenson in a release.

Since its founding in 1987, SXSW has grown from a little Texas music festival to an internationally renowned festival that attracts the brightest minds in technology, film, music, and comedy. The 2021 digital version will capture much of that spirit, with signature keynote addresses, conference sessions, music showcases, comedy sets, film screenings, and other "unexpected discoveries."

Badges are on sale beginning today, and are priced at $149 for a limited time. By March 2021, that rate will go up to $399. Student and group discounts are also available. Digital passes grant access to the following:

  • SXSW Keynotes and Featured Speakers
  • Mentor sessions and workshops
  • SXSW Film Festival screenings, events, and exclusive premieres
  • SXSW Music Festival showcases and events
  • SXSW Comedy Festival content
  • Online exhibitions
  • Networking opportunities
SXSW's startup pitch competition will return in 2021 too. Applications are open online — early bird applications for $29 will be accepted until November 24, and regularly priced submissions are accepted up to January 8 for $59.

A lineup isn't yet available — SXSW usually announces details in the two months leading up to the festival — but community voting on SXSW session proposals is currently underway through November 20. Peruse the more than 1,500 panels here, and vote for the ones you want to attend next year.

"It's a new day for America and for the world," Swenson adds. "We have the opportunity to face challenges that affect us all, and we're honored to bring you the conversations that will renew your hope in tomorrow."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”